Miracle Mile Advisors’s GSK GSK Stock Holding History

Miracle Mile Advisors’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$331K	Sell	6,320 -1,235	-16%	-$65.3K	﹤0.01%	767
2026 Q1	$417K	Buy	7,555 +302	+4%	+$16.4K	0.01%	630
2025 Q4	$356K	Buy	7,253 +1,047	+17%	+$48.8K	0.01%	660
2025 Q3	$268K	Sell	6,206 -213	-3%	-$8.32K	﹤0.01%	710
2025 Q2	$247K	Buy	+6,419	New	+$245K	﹤0.01%	637
2024 Q4	–	Sell	-9,501	Closed	-$388K	–	650
2024 Q3	$388K	Sell	9,501 -799	-8%	-$32.7K	0.01%	385
2024 Q2	$397K	Sell	10,300 -74	-0.7%	-$3.11K	0.01%	368
2024 Q1	$445K	Buy	10,374 +119	+1%	+$4.91K	0.01%	359
2023 Q4	$380K	Sell	10,255 -20	-0.2%	-$718	0.01%	365
2023 Q3	$372K	Buy	10,275 +20	+0.2%	+$710	0.01%	371
2023 Q2	$365K	Hold	10,255	–	–	0.01%	393
2023 Q1	$365K	Hold	10,255	–	–	0.01%	405
2022 Q4	$360K	Sell	10,255 -1,000	-9%	-$33.3K	0.01%	399
2022 Q3	$331K	Sell	11,255 -13,865	-55%	-$525K	0.02%	347
2022 Q2	$1.37M	Hold	25,120	–	–	0.06%	185
2022 Q1	$1.37M	Buy	+25,120	New	+$1.36M	0.06%	199
2019 Q2	–	Sell	-36,080	Closed	-$1.89M	–	269
2019 Q1	$1.89M	Buy	+36,080	New	+$1.8M	0.15%	116

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Miracle Mile Advisors's GSK Position: Q2 2026 in Review

Miracle Mile Advisors reduced its GSK (GSK) stake by 16% in Q2 2026, selling an estimated $65.3K and leaving 6,320 shares worth $331K. The position accounts for ﹤0.01% of the portfolio, ranked #767.

Miracle Mile Advisors first reported a position in GSK in Q1 2019 and has held it in 17 quarters since. The position peaked at $1.89M in Q1 2019. 1,040 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Miracle Mile Advisors held 6,320 shares of GSK worth $331K as of Q2 2026.
Miracle Mile Advisors sold 1,235 GSK shares in Q2 2026, an estimated $65.3K.
GSK made up ﹤0.01% of Miracle Mile Advisors's portfolio in Q2 2026, its #767 holding.
Miracle Mile Advisors first reported a position in GSK in Q1 2019 and has held it in 17 quarters since.
Miracle Mile Advisors's GSK position peaked at $1.89M in Q1 2019.
1,040 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Miracle Mile Advisors's 13F filing for Q2 2026, filed 22 Jul 2026.